SCHEMBL7185261

SCHEMBL7185261

C[C@H](CO)Nc1ccc(C#N)cc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
ABCC9 O60706 1/20 0.39
ABCC8 Q09428 1/20 0.39
KCNJ11 Q14654 1/20 0.39
KCNJ8 Q15842 1/20 0.39
MAPK8 P45983 2/20 0.38
MAPK9 P45984 2/20 0.38
MAPK10 P53779 1/20 0.38
CXCR2 P25025 1/20 0.35
SCN9A Q15858 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ABCB1 P08183 1/20 0.34
BCL6 P41182 2/20 0.34
IRAK4 Q9NWZ3 6/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7179367 1.00 KDM4E (0.48) KDM4EALDH1A1GAAABCC9ABCC8
SCHEMBL2339309 0.82 KDM4E (0.54) KDM4EALDH1A1GAAABCC9ABCC8
SCHEMBL580661 0.82 PDK1 (0.45) ABCC9ABCC8KCNJ11KCNJ8CXCR2
SCHEMBL7185647 0.80 KDM4E (0.44) KDM4EALDH1A1GAAABCC9ABCC8
SCHEMBL7183015 0.80 KDM4E (0.44) KDM4EALDH1A1GAAABCC9ABCC8
SCHEMBL16722382 0.76 AAK1 (0.42) KDM4EMAPK1
SCHEMBL16722381 0.76 AAK1 (0.42) KDM4EMAPK1
SCHEMBL7190773 0.76 KAT2B (0.52) ALDH1A1KMT2A
SCHEMBL7182036 0.76 KAT2B (0.52) ALDH1A1KMT2A
SCHEMBL16155889 0.76 KDM4E (0.54) KDM4EALDH1A1GAACXCR2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed